The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
- PMID: 10646108
- DOI: 10.1359/jbmr.2000.15.1.2
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
Abstract
Although multiple hormones and cytokines regulate various aspects of osteoclast formation, the final two effectors are osteoprotegerin ligand (OPG-L)/osteoclast differentiation factor (ODF), a recently cloned member of the tumor necrosis factor superfamily, and macrophage colony-stimulating factor. OPG-L/ODF is produced by osteoblast lineage cells and exerts its biological effects through binding to its receptor, osteoclast differentiation and activation receptor (ODAR)/receptor activator of NF-kappa B (RANK), on osteoclast lineage cells, in either a soluble or a membrane-bound form, the latter of which requires cell-to-cell contact. Binding results in rapid differentiation of osteoclast precursors in bone marrow to mature osteoclasts and, at higher concentrations, in increased functional activity and reduced apoptosis of mature osteoclasts. The biological activity of OPG-L/ODF is neutralized by binding to osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF), a member of the TNF-receptor superfamily that also is secreted by osteoblast lineage cells. The biological importance of this system is underscored by the induction in mice of severe osteoporosis by targeted ablation of OPG/OCIF and by the induction of osteopetrosis by targeted ablation of OPG-L/ODF or overexpression of OPG/OCIF. Thus, osteoclast formation may be determined principally by the relative ratio of OPG-L/ODF to OPG/OCIF in the bone marrow microenvironment, and alterations in this ratio may be a major cause of bone loss in many metabolic disorders, including estrogen deficiency and glucocorticoid excess. That changes in but two downstream cytokines mediate the effects of large numbers of upstream hormones and cytokines suggests a regulatory mechanism for osteoclastogenesis of great efficiency and elegance.
Similar articles
-
A novel molecular mechanism modulating osteoclast differentiation and function.Bone. 1999 Jul;25(1):109-13. doi: 10.1016/s8756-3282(99)00121-0. Bone. 1999. PMID: 10423033
-
Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.Biochem Biophys Res Commun. 1998 May 19;246(2):337-41. doi: 10.1006/bbrc.1998.8610. Biochem Biophys Res Commun. 1998. PMID: 9610359
-
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.Cancer. 2003 Feb 1;97(3 Suppl):802-12. doi: 10.1002/cncr.11134. Cancer. 2003. PMID: 12548579 Review.
-
Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.J Bone Miner Res. 2001 Nov;16(11):2074-81. doi: 10.1359/jbmr.2001.16.11.2074. J Bone Miner Res. 2001. PMID: 11697804
-
[Osteoclastogenesis Inhibitory Factor (OCIF) /Osteoprotegerin (OPG) as a new therapeutic agent for osteoporosis].Clin Calcium. 2005 Jan;15(1):35-42. Clin Calcium. 2005. PMID: 15632471 Review. Japanese.
Cited by
-
Coupling factors involved in preserving bone balance.Cell Mol Life Sci. 2019 Apr;76(7):1243-1253. doi: 10.1007/s00018-018-2981-y. Epub 2018 Dec 4. Cell Mol Life Sci. 2019. PMID: 30515522 Free PMC article. Review.
-
Rank-Rankl-Opg Axis in Multiple Sclerosis: The Contribution of Placenta.Cells. 2022 Apr 15;11(8):1357. doi: 10.3390/cells11081357. Cells. 2022. PMID: 35456036 Free PMC article.
-
[Particular features of steroid-induced osteoporosis].Orthopade. 2007 Aug;36(8):708, 710-3. doi: 10.1007/s00132-007-1117-0. Orthopade. 2007. PMID: 17643225 Review. German.
-
IL-27 Modulates the Cytokine Secretion in the T Cell-Osteoclast Crosstalk During HIV Infection.Front Immunol. 2022 Apr 5;13:818677. doi: 10.3389/fimmu.2022.818677. eCollection 2022. Front Immunol. 2022. PMID: 35479090 Free PMC article.
-
p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts.Immunol Invest. 2004 May;33(2):213-33. doi: 10.1081/imm-120034231. Immunol Invest. 2004. PMID: 15195698 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources